Xiao, Yinzong
van Gemert, Caroline
Howell, Jess
Wallace, Jack
Richmond, Jacqueline
Adamson, Emily
Thompson, Alexander
Hellard, Margaret
Funding for this research was provided by:
The Victorian Operational Infrastructure Support Program
Melbourne Research Scholarship
Australian National Health and Medical Research Council
University of Melbourne Faculty Trust Fellowship
Article History
Received: 20 September 2021
Accepted: 25 May 2022
First Online: 2 June 2022
Declarations
:
: Ethics approval was obtained from the Alfred Hospital Ethics Committee (630/17). Informed consent was obtained from all participants. All methods were performed in accordance with the Declaration of Helsinki.
: Not applicable.
: MH receives funding from Gilead Sciences and Abbvie for investigator-initiated research unrelated to hepatitis B. JH has received speaker fees and investigator-initiated grants from Gilead Sciences. AT has received consulting fees from Gilead, Abbvie, Roche, BMS, Merck, Immunocore, Janssen, Assembly Biosciences, Arbutus, Eisai, Ipsen and Bayer, speaker fees from Gilead Sciences, and investigator-initiated grants from Gilead Sciences. YX, CvG, JW, JR, and EA have no competing interest to declare.